Onboarding with elexacaftor-tezacaftor-ivacaftor (Trikafta, Vertex) is keeping clinical pharmacists across the country busy since the game-changing new cystic fibrosis (CF) drug was approved by the FDA in October 2019.
The transmembrane conductance regulator (CFTR) modulator therapy is approved for patients aged 12 years and older with CF who have at least one F508del mutation in the CFTR gene—an estimated 90% of patients with CF. Previous CFTR modulators were only effective